ALKS Q2 2025 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$391M-2.1% YoY

Gross Profit

$341M87.3% margin

Operating Income

$93M23.8% margin

Net Income

$87M22.3% margin

EPS (Diluted)

$0.52

QoQ Revenue Growth

+27.5%

Cash Flow

Operating Cash Flow

$150M

Free Cash Flow

$137M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$628M

Stockholders' Equity

$1.6B

Cash & Equivalents

$521M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$391M	$399M	-2.1%
Gross Profit	$341M	$338M	+1.0%
Operating Income	$93M	$110M	-15.4%
Net Income	$87M	$91M	-4.7%

Revenue Segments

Product

$307M50%

Vivitrol

$122M20%

Aristada And Aristada Initio

$101M16%

L Y B A L V I

$84M14%